33 reports of this reaction
3.2% of all PHENAZOPYRIDINE HYDROCHLORIDE reports
#2 most reported adverse reaction
DYSPNOEA is the #2 most commonly reported adverse reaction for PHENAZOPYRIDINE HYDROCHLORIDE, manufactured by i-Health, Inc.. There are 33 FDA adverse event reports linking PHENAZOPYRIDINE HYDROCHLORIDE to DYSPNOEA. This represents approximately 3.2% of all 1,029 adverse event reports for this drug.
Patients taking PHENAZOPYRIDINE HYDROCHLORIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among PHENAZOPYRIDINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for PHENAZOPYRIDINE HYDROCHLORIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 33 FDA reports for PHENAZOPYRIDINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.2% of all adverse event reports for PHENAZOPYRIDINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking PHENAZOPYRIDINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.